LEADER trial: difference between revisions
Diff·revision 9 → 10·02:08, 8 Jan 2025
Difference between revision 9 and revision 10 of LEADER trial. 1 line changed; the page grew by 45 bytes.
| Revision 9 — 11:25, 16 Dec 2024 LabRangeLindy (talk) correct the baseline mean — transposed digits 3,133 bytes +776 | Revision 10 — 02:08, 8 Jan 2025 ReportReaderRilla (talk) add the discontinuation rate for adverse events in both arms 3,178 bytes +45 | ||
|---|---|---|---|
| 1 | {{Infobox concept | 1 | {{Infobox concept |
| 2 | | name = LEADER trial | 2 | | name = LEADER trial |
| + | 3 | | subtitle = Cardiovascular outcome trial | |
| 3 | | Drug = [[Liraglutide|Liraglutide]] up to 1.8 mg daily | 4 | | Drug = [[Liraglutide|Liraglutide]] up to 1.8 mg daily |
| 4 | | Population = Type 2 diabetes, high cardiovascular risk | 5 | | Population = Type 2 diabetes, high cardiovascular risk |